Dr. Yeku is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit Street
Boston, MA 02114Phone+1 617-219-1230
Summary
- Dr. Oladapo Yeku is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital and Newton-Wellesley Hospital. He received his medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 8 years. He specializes in gynecologic cancer and is experienced in vulvar carcinoma and ovarian cancer. He has more than 30 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2018
UPMC Medical EducationResidency, Internal Medicine, 2012 - 2014
Stony Brook University Health Sciences Center School of MedicineClass of 2012
Medgar Evers CollegeBS, Biology, Summa Cum Laude, 2001 - 2005
Certifications & Licensure
MA State Medical License 2018 - 2027
NY State Medical License 2014 - 2025
PA State Medical License 2012 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma Start of enrollment: 2018 Aug 27
- A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) Start of enrollment: 2020 Jan 02
- PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Start of enrollment: 2020 Aug 11
Publications & Presentations
PubMed
- A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors.Gregory M Cote, Bose S Kochupurakkal, Khanh Do, Andrea Bullock, Michael L Cheng
Clinical Cancer Research. 2024-10-25 - 1 citationsHigh-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options.Yusuke Matoba, Kyle M Devins, Lara Milane, William B Manning, Varvara Mazina
Reproductive Sciences. 2024-09-01 - Author Correction: Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair.Yumin Wang, Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu
Nature Communications. 2024-05-07
Grant Support
- Facilitated Insulin Secretion VIA Ablation Of A Compartmentalized Pool Of PIP2National Institute Of Diabetes And Digestive And Kidney Diseases2008–2010
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
